Cost-outcome description of clinical pharmacist interventions in a university teaching hospital

BMC Health Services Research

Suzanne McCarthy³  Deirdre Lynch²  Noel Woods¹  Stephen Byrne³  James Gallagher⁴ 

[1] Centre for Policy Studies, University College Cork, Cork, Ireland;Pharmacy Department, Cork University Hospital, Cork, Ireland;Clinical Pharmacy Research Group, School of Pharmacy, University College Cork, Cork, Ireland;HRB Clinical Research Facility at UCC, Mercy University Hospital, Cork, Ireland

关键词: Cost avoidance;    Clinical pharmacy services;    Ireland;    Health care economics;    Adverse drug events;    Hospital pharmacy;   

Others  :  1132714
DOI  :  10.1186/1472-6963-14-177

 received in 2013-11-20, accepted in 2014-03-25,  发布年份 2014

【 摘 要 】

Background

Pharmacist interventions are one of the pivotal parts of a clinical pharmacy service within a hospital. This study estimates the cost avoidance generated by pharmacist interventions due to the prevention of adverse drug events (ADE). The types of interventions identified are also analysed.

Methods

Interventions recorded by a team of hospital pharmacists over a one year time period were included in the study. Interventions were assigned a rating score, determined by the probability that an ADE would have occurred in the absence of an intervention. These scores were then used to calculate cost avoidance. Net cost benefit and cost benefit ratio were the primary outcomes. Categories of interventions were also analysed.

Results

A total cost avoidance of €708,221 was generated. Input costs were calculated at €81,942. This resulted in a net cost benefit of €626,279 and a cost benefit ratio of 8.64: 1. The most common type of intervention was the identification of medication omissions, followed by dosage adjustments and requests to review therapies.

Conclusion

This study provides further evidence that pharmacist interventions provide substantial cost avoidance to the healthcare payer. There is a serious issue of patient’s regular medication being omitted on transfer to an inpatient setting in Irish hospitals.

【 授权许可】

   
2014 Gallagher et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Halvorsen KH, Stensland P, Granas AG: A qualitative study of physicians‘ and nurses’ experiences of multidisciplinary collaboration with pharmacists participating at case conferences. Int J Pharm Pract 2011, 19(5):350-357.
• [2]Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL: Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med 2006, 166(9):955-964.
• [3]Khalili H, Karimzadeh I, Mirzabeigi P, Dashti-Khavidaki S: Evaluation of clinical pharmacist’s interventions in an infectious diseases ward and impact on patient’s direct medication cost. Eur J Intern Med 2013, 24(3):227-233.
• [4]Klopotowska JE, Kuiper R, van Kan HJ, de Pont AC, Dijkgraaf MG, Lie-A-Huen L, Vroom MB, Smorenburg SM: On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study. Crit Care 2010, 14(5):R174. BioMed Central Full Text
• [5]Kopp BJ, Mrsan M, Erstad BL, Duby JJ: Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm 2007, 64(23):2483-2487.
• [6]Lada P, Delgado G Jr: Documentation of pharmacists’ interventions in an emergency department and associated cost avoidance. Am J Health Syst Pharm 2007, 64(1):63-68.
• [7]Olson LM, Desai S, Soto ML, Namazifard S, Quelland AK, Erstad BL: Evaluation of pharmacists’ interventions at a university teaching hospital. Can J Hosp Pharm 2005, 58(1):20-25.
• [8]Shen J, Sun Q, Zhou X, Wei Y, Qi Y, Zhu J, Yan T: Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital. Int J Clin Pharm 2011, 33(6):929-933.
• [9]Alderman CP, Farmer C: A brief analysis of clinical pharmacy interventions undertaken in an Australian teaching hospital. J Qual Clin Pract 2001, 21(4):99-103.
• [10]Marriott JL, Nation RL, Roller L, Costelloe M, Galbraith K, Stewart P, Charman WN: Pharmacy education in the context of Australian practice. Am J Pharm Educ 2008, 72(6):131.
• [11]Sosabowski MH, Gard PR: Pharmacy education in the United Kingdom. Am J Pharm Educ 2008, 72(6):130.
• [12]Bradley MC, Fahey T, Cahir C, Bennett K, O’Reilly D, Parsons C, Hughes CM: Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol 2012, 68(10):1425-1433.
• [13]Budnitz DS, Lovegrove MC, Shehab N, Richards CL: Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365(21):2002-2012.
• [14]Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, Kosterink JG: Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands. Drug Saf 2011, 34(11):1089-1100.
• [15]O’Sullivan DP, O’Mahony D, Parsons C, Hughes C, Murphy K, Patterson S, Byrne S: A prevalence study of potentially inappropriate prescribing in Irish long-term care residents. Drugs & aging 2013, 30(1):39-49.
• [16]Ryan C, O’Mahony D, Kennedy J, Weedle P, Byrne S: Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 2009, 68(6):936-947.
• [17]Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP: Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997, 277(4):301-306.
• [18]De Rijdt T, Willems L, Simoens S: Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm 2008, 65(12):1161-1172.
• [19]Dooley MJ, Allen KM, Doecke CJ, Galbraith KJ, Taylor GR, Bright J, Carey DL: A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. Br J Clin Pharmacol 2004, 57(4):513-521.
• [20]Hughes DA: From NCE to NICE: the role of pharmacoeconomics. Br J Clin Pharmacol 2010, 70(3):317-319.
• [21]Hughes DA: Pharmacoeconomics. Br J Clin Pharmacol 2012, 73(6):968-972.
• [22]Bond CA, Raehl CL: Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy 2007, 27(4):481-493.
• [23]MacLaren R, Bond CA, Martin SJ, Fike D: Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med 2008, 36(12):3184-3189.
• [24]Campbell AR, Nelson LA, Elliott E, Hieber R, Sommi RW: Analysis of cost avoidance from pharmacy students’ clinical interventions at a psychiatric hospital. Am J Pharm Educ 2011, 75(1):8.
• [25]Nesbit TW, Shermock KM, Bobek MB, Capozzi DL, Flores PA, Leonard MC, Long JK, Militello MA, White DA, Barone LD, Goldman MP, Kvancz DA: Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health Syst Pharm 2001, 58(9):784-790.
• [26]Consolidated Salary Scales in Accordance with Financial Emergency Measures in the Public Interest Act 2013 http://www.hse.ie/eng/staff/Benefits_Services/pay/July%202013.pdf webcite
• [27]Health Information and Quality Authority: Guidelines for the Budget Impact Analysis of Health Technologies in Ireland. Dublin: Health Information and Quality Authority; 2010.
• [28]Department of An Taoiseach: How to Conduct a Regulatory Impact Analysis. Dublin: Department of an Taoiseach; 2009. http://www.taoiseach.gov.ie/eng/Publications/Publications_Archive/Publications_2011/Revised_RIA_Guidelines_June_2009.pdf webcite
• [29]Health Information and Quality Authority: Guidelines for the evaluation of health technologies in Ireland. Dublin: Health Information and Quality Authority; 2010. http://www.hiqa.ie/healthcare/health-technology-assessment/guidelines.z webcite
• [30]Rottenkolber D, Hasford J, Stausberg J: Costs of adverse drug events in German hospitals–a microcosting study. Value Health 2012, 15(6):868-875.
• [31]Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL, Adverse Drug Events Prevention Study Group: The costs of adverse drug events in hospitalized patients. JAMA 1997, 277(4):307-311.
• [32]Heerey A, McGowan B, Ryan M, Barry M: Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res 2002, 2(1):29-33.
• [33]National Casemix Programme: Ready Reckoner of Acute Hospital inpatient and day case activity and costs (summarised by DRG) relating to 2011 costs and activity. Ireland: Health Service Executive; 2013.
• [34]CA R: Arzneimittelmanagement im Krankenhaus. Eine theoretische und empirische Analyse. Lang: Frankfurt am Main; 2007.
• [35]Anderson R: Systematic reviews of economic evaluations: utility or futility? Health Econ 2010, 19(3):350-364.
• [36]Anderson SV, Schumock GT: Evaluation and justification of clinical pharmacy services. Expert Rev Pharmacoecon Outcomes Res 2009, 9(6):539-545.
• [37]Galvin M, Jago-Byrne MC, Fitzsimons M, Grimes T: Clinical pharmacist’s contribution to medication reconciliation on admission to hospital in Ireland. Int J Clin Pharm 2013, 35(1):14-21.
• [38]Bracey G, Miller G, Franklin BD, Jacklin A, Gaskin G: The contribution of a pharmacy admissions service to patient care. Clin Med 2008, 8(1):53-57.
• [39]Tam VC, Knowles SR, Cornish PL, Fine N, Marchesano R, Etchells EE: Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review. CMAJ 2005, 173(5):510-515.
• [40]International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2D. Genève: ICH Secretariat; 2003.
• [41]Patanwala AE, Hays DP, Sanders AB, Erstad BL: Severity and probability of harm of medication errors intercepted by an emergency department pharmacist. Int J Pharm Pract 2011, 19(5):358-362.
• [42]Paradis AR, Stewart VT, Bayley KB, Brown A, Bennett AJ: Excess cost and length of stay associated with voluntary patient safety event reports in hospitals. Am J Med Qual 2009, 24(1):53-60.
• [43]Molloy D, Molloy A, O’Loughlin C, Falconer M, Hennessy M: Inappropriate use of proton pump inhibitors. Ir J Med Sci 2010, 179(1):73-75.
• [44]Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K: Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Serv Res 2012, 12:408. BioMed Central Full Text
• [45]Crowley RK, Fitzpatrick F, Solanki D, FitzGerald S, Humphreys H, Smyth EG: Vancomycin administration: the impact of multidisciplinary interventions. J Clin Pathol 2007, 60(10):1155-1159.
• [46]Dunn K, O’Reilly A, Silke B, Rogers T, Bergin C: Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. Int J Clin Pharm 2011, 33(2):208-214.